Atomwise
Latest round
- Series C
Last raised
- Mar 2024
Total raised
- $219M
Investors
- 12
About Atomwise
Atomwise, Inc.Founded in 2012 and headquartered in San Francisco, US, Atomwise, Inc. specializes in leveraging AI for drug discovery. The company has not undergone any significant operational pivots and does not have known parent or subsidiary companies. The founding team includes Abraham Heifets and Izhar Wallach, with Heifets serving as CEO.Atomwise harnesses artificial intelligence to improve drug discovery, primarily through its proprietary machine learning-based discovery engine. This technology utilizes convolutional neural networks and extensive chemical libraries to identify and develop small molecule medicines. Atomwise's product offerings include both wholly owned and co-developed assets, addressing critical healthcare challenges related to drug efficacy and safety.Atomwise generates revenue through B2B partnerships and collaborations with pharmaceutical and biotechnology companies. Its business model includes licensing its AI technology and providing tailored drug discovery services, which may also involve milestone payments and royalties tied to the success of compounds developed.In March 2024, Atomwise, Inc.
Who invested in Atomwise
12 investors across 5 rounds
See all investors in Atomwise
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Atomwise
Who invested in Atomwise?
Atomwise has 12 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Atomwise raised?
Atomwise has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Atomwise last raise money?
Atomwise's most recent round on record is a Series C, in Mar 2024.
What does Atomwise do?
Atomwise is a biotechnology company.
Where is Atomwise headquartered?
Atomwise is headquartered in San Francisco, US.
Which VCs invest in companies like Atomwise?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Atomwise's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Atomwise? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.